Abstract

CD34-positive monocytes (CD34+mono) have recently been identified in grafts mobilized by granulocyte-colony stimulating factor. We analyzed transplant outcomes of 73 patients whose donor’s peripheral blood cells were cryopreserved during mobilization. CD34+mono was detected more frequently in male donors (67% vs. 40%, P = 0.03), while the detection of CD34+mono in donors was not associated with the patient background. Although there was no significant difference in overall survival in the whole cohort, the detection of CD34+mono in donors were significantly associated with a decreased risk of non-relapse mortality (HR 0.23, P = 0.035). Fatal infectious events tended to be less frequent in donors with CD34+mono. Gene expression profile analyses of CD34+mono in humans revealed that the expressions of pro-inflammatory cytokines like IL6, CCL3, IL8, VEGFA, and IL1A were elevated in CD34+mono, and those cytokines were enriched in the immune response, especially against infectious pathogens in the gene ontology analyses. In addition, the expression of CD83 was specifically increased in CD34+mono. It might play a role of antigen presentation in the immune network, leading in a clinical benefit against infections. Further investigations will be required to confirm the biological functions and clinical roles of CD34+mono in transplantation.

Highlights

  • CD34-positive monocytes (CD34+mono) have recently been identified in grafts mobilized by granulocyte-colony stimulating factor

  • This study explored the impact of the detection of CD34+mono in donor peripheral blood on clinical outcomes after haematopoietic cell transplantation (HCT), and demonstrated the gene expression profiles (GEP) of CD34+mono compared with CD34+ cells and monocytes

  • Through GEP, we found that the differentially expressed genes in CD34+mono were involved mainly in the pathways of immune processes against pathogens

Read more

Summary

Introduction

CD34-positive monocytes (CD34+mono) have recently been identified in grafts mobilized by granulocyte-colony stimulating factor. CD34-positive monocytes (CD34+mono) have newly been reported in G-CSF-mobilized PBSC grafts, and have been demonstrated to exhibit immunosuppressive activity in animal models[12]. It is unclear whether the detection of CD34+mono in donors could be associated with a decreased incidence of GVHD or non-relapse mortality (NRM) after HCT in actual clinical settings. This study explored the impact of the detection of CD34+mono in donor peripheral blood on clinical outcomes after HCT, and demonstrated the gene expression profiles (GEP) of CD34+mono compared with CD34+ cells and monocytes

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.